Impact Factor 6.429

The 5th most cited journal in Immunology

This article is part of the Research Topic

Regulation of Inflammation in Chronic Disease

Original Research ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Immunol. | doi: 10.3389/fimmu.2017.01531

Gp96 Peptide Antagonist gp96-II Confers Therapeutic Effects in Murine Intestinal Inflammation

 Claudia A. Nold-Petry1, 2*, Marcel F. Nold1, 2, Ofer Levy3, Yossef Kliger3, Anat Oren3, Itamar Borukhov3,  Christoph Becker4,  Stefan Wirtz4,  Markus Neurath4 and Charles A. Dinarello4, 5
  • 1Hudson Institute of Medical Research, Australia
  • 2Department of Paediatrics, Monash University, Australia
  • 3Compugen Ltd, Israel
  • 4Medical Clinic 1, Friedrich Alexander University Erlangen-Nuremberg, Germany
  • 5Department of Medicine, University of Colorado Denver, United States

ABSTRACT
Background: The expression of heat shock protein gp96 is strongly correlated with the degree of tissue inflammation in ulcerative colitis and Crohn’s disease, leading us to the hypothesis that inhibition of expression via gp96-II peptide prevents intestinal inflammation.
Methods: We employed daily injections of gp96-II peptide in two murine models of intestinal inflammation, the first resulting from five daily injections of IL-12/IL-18, the second via a single intra-rectal application of TNBS (2,4,6-trinitrobenzenesulfonic acid). We also assessed the effectiveness of gp96-II peptide in murine and human primary cell culture.
Results: In the IL-12/IL-18 model, all gp96-II peptide treated animals survived until day 5, whereas 80% of placebo-injected animals died. Gp96-II peptide reduced IL-12/IL-18-induced plasma IFNγ by 89%, IL-1β by 63%, IL-6 by 43% and TNF by 70% compared to controls. The clinical assessment Disease Activity Index (DAI) of intestinal inflammation severity was found to be significantly lower in the gp96-II treated animals when compared to vehicle injected mice. Gp96-II peptide treatment in the TNBS model limited weight loss to 5% on day 7 compared with prednisolone treatment whereas placebo-treated animals suffered a 20% weight loss. Histological disease severity was reduced equally by prednisolone (by 40%) and gp96-II peptide (35%). Mice treated with either gp96-II peptide or prednisolone exhibited improved endoscopic scores compared with vehicle-treated control mice: vascularity, fibrin, granularity, and translucency scores were reduced by up to 49% by prednisolone and by up to 30% by gp96-II peptide
In vitro, gp96-II peptide reduced TLR2-, TLR4- or IL-12/IL18-induced cytokine expression in murine splenocytes, with declines in constitutive IL-6 (54%), LPS-induced TNF (48%) and IL-6 (81%), and in Staphylococcus epidermidis (St. epi.)-induced TNF (67%) and IL-6 (81%), as well as IL-12/IL-18-induced IFNγ (75%). Gp96-II peptide reduced IL 1β, IL-6, TNF, and GM-CSF in human peripheral blood mononuclear cells (PBMC) to a similar degree without affecting cell-viability, whereas RANTES, IL-25, and MIF were 2-3-fold increased.
Conclusion: Gp96-II peptide protects against murine intestinal inflammation by regulating inflammation in vivo and in vitro, pointing to its promise as a novel treatment for inflammatory bowel disease.

Keywords: Gp96, Cytokines and inflammation, biologics, Therapeutics, immunemodulatory, anti-inflammtory agent, intestinal inflammation, IBD

Received: 14 Jul 2017; Accepted: 27 Oct 2017.

Edited by:

Guixiu Shi, Xiamen University, China

Reviewed by:

Dipyaman Ganguly, Indian Institute of Chemical Biology (CSIR), India
Bo-Zong Shao, Second Military Medical University, China
Ka Man Law, University of California, Los Angeles, United States  

Copyright: © 2017 Nold-Petry, Nold, Levy, Kliger, Oren, Borukhov, Becker, Wirtz, Neurath and Dinarello. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Dr. Claudia A. Nold-Petry, Hudson Institute of Medical Research, Clayton, Australia, claudia.nold@monash.edu